Other
CN
EU
USA
Description: Navitoclax (formerly ABT-263) is a novel, highly potent, orally bioavailable small-molecule inhibitor of the BCL (B-cell leukemia) protein family such as Bcl-xL, Bcl-2 and Bcl-w with Ki of ~ 0.5 nM, ~1 nM and ~1 nM in cell-free assays. It has potential anticancer activity and is currently undergoing Phase studies for the treatment of both solid and liquid tumors. ABT-263 mimicks the Bad-like BH3 and binds to Bcl-2 family proteins Bcl-2, Bcl-xl and Bcl-w which disrupts the interaction between Bcl-2/Bcl-xl /Bcl-w and pro-apoptotic proteins such as Bim(Bcl-2-interacting mediator of cell death), Bad (Bcl-2-associated death promoter) and Bak(BCL2-antagonist/killer 1), eventually it will trigger the caspases-initiated cell death pathway to induce apoptosis.
References: Cancer Res. 2008, 68(9), 3421-428.; Clin Cancer Res, 2008, 14(11), 3268-77.
Product Catalog 2023
Guide to Product Handling
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Lot#: V000301,Purity ≥98%
COA
MSDS
NMR
Lot#: V000302,Purity ≥98%